PDCD1 and neoplasm: Consequently, immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 antibodies, are increasingly being tested as therapeutic strategies to counteract immune evasion in hypoxic tumors and restore effective anti-tumor immunity[18,19].